title: Novel opportunities for next-generation probiotics targeting metabolic syndrome.
abstract: Various studies have described the beneficial effects of specific bacteria on the characteristics of metabolic syndrome. Intestinal microbiota might therefore represent a modifiable trait for translational intervention to improve the metabolic profiles of obese and type 2 diabetic patients. However, identifying potential probiotic strains that can effectively colonize the gastrointestinal tract and significantly affect host metabolism has been challenging. This review aims to summarize the notable advances and contributions in the field that may prove useful for identifying next-generation probiotics that target metabolic syndrome and its related disorders.
authors.affiliation: Université Catholique de Louvain, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), Metabolism and Nutrition Research Group, Av. E. Mounier, 73 Box B1.73.11, B-1200 Brussels, Belgium. Electronic address: patrice.cani@uclouvain.be.
authors.forename: Patrice D
authors.initials: PD
authors.lastname: Cani
authors.affiliation: Université Catholique de Louvain, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), Metabolism and Nutrition Research Group, Av. E. Mounier, 73 Box B1.73.11, B-1200 Brussels, Belgium.
authors.forename: Matthias
authors.initials: M
authors.lastname: Van Hul
mesh_terms: D000581:Amidohydrolases / Q000378:metabolism; D000818:Animals; D001644:Bifidobacterium / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007778:Lactobacillus / Q000378:metabolism; D024821:Metabolic Syndrome / Q000178:diet therapy*; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D000581:Amidohydrolases; C023154:choloylglycine hydrolase